Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CADL | PRESS-RELEASE | bullish | 7/10 | Candel Therapeutics announced the initiation of a global pivotal Phase 3 AURORA trial (NCT07660094) evaluating aglatimag | Jun 30, 2026 |
| AKBA | 8-K | bullish | 7/10 | Akebia Therapeutics and U.S. Renal Care announced that the VOICE trial (Vafseo vs. ESA in 2,116 dialysis patients) met i | Jun 30, 2026 |
| STOK | 8-K | bullish | 6/10 | Stoke Therapeutics completed enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen for Dravet syndro | Jun 30, 2026 |
| MNPR | 8-K | bullish | 5/10 | Monopar Therapeutics announced that the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate c | Jun 30, 2026 |
| PVLA | 8-K | neutral | 2/10 | Palvella Therapeutics appointed Matthew Pauls as a Class I director, expanding the board from seven to eight members. Mr | Jun 30, 2026 |
| PCRX | 8-K | bullish | 7/10 | Pacira BioSciences has agreed to sell its iovera handheld cryoanalgesia device business to Zimmer Biomet for up to $140M | Jun 30, 2026 |
| PYXS | PRESS-RELEASE | mixed | 6/10 | Pyxis Oncology announced a $50M private placement (plus up to $64M from warrants) led by BVF Partners, extending cash ru | Jun 30, 2026 |
| IFRX | PRESS-RELEASE | bullish | 7/10 | InflaRx announced it is assessing a broader development and registrational strategy for ANCA-associated vasculitis (AAV) | Jun 30, 2026 |
| PSTV | PRESS-RELEASE | neutral | 4/10 | Plus Therapeutics announced a corporate rebranding to Cerenome and a Nasdaq ticker change to CNSY effective August 3, 20 | Jun 30, 2026 |
| SILO | DEFA14A | bearish | 7/10 | Silo Pharma filed definitive additional proxy materials for its 2026 Annual Meeting, proposing a massive increase in aut | Jun 30, 2026 |
| ACIU | PRESS-RELEASE | mixed | 4/10 | AC Immune reported interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer's disease. The | Jun 30, 2026 |
| CLLS | COURT-RULING | bullish | 6/10 | The District of Delaware granted-in-part Cellectis's motion to stay the patent infringement action brought by Factor Bio | Jun 30, 2026 |
| ADXN | 6-K | bearish | 5/10 | Addex Therapeutics reported that shareholders approved all resolutions at the 2026 AGM, including amendments to increase | Jun 30, 2026 |
| HCM | 6-K | neutral | 3/10 | HUTCHMED filed a Form 6-K announcing that it will release its 2026 half-year financial results on July 30, 2026, with we | Jun 30, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on June 30, 2026, reporting a change in substantial holding (Exhibit 99.1). The f | Jun 30, 2026 |
| BIVI | EFFECT | bearish | 5/10 | BioVie Inc.'s S-3 shelf registration statement (File No. 333-296924) became effective on June 29, 2026, allowing the com | Jun 30, 2026 |
| PRFX | EFFECT | bearish | 7/10 | The SEC declared effective PRF Technologies' F-1 registration statement (File No. 333-296943) on June 29, 2026, enabling | Jun 30, 2026 |
| HCM | PRESS-RELEASE | neutral | 1/10 | HUTCHMED (China) Limited announced it will report its half-year 2026 results on July 30, 2026. | Jun 30, 2026 |
| NVCT | PRESS-RELEASE | bearish | 6/10 | Nuvectis Pharma priced an underwritten public offering of 5,000,000 shares at $20.00/share for gross proceeds of $100 mi | Jun 29, 2026 |
| CAPR | CLUSTER | neutral | 3/10 | Two C-suite insiders at CAPR (CFO and EVP/General Counsel) exercised stock options and concurrently sold shares in a nea | Jun 29, 2026 |
| ARQT | PRESS-RELEASE | bullish | 7/10 | Arcutis Biotherapeutics received FDA approval to expand ZORYVE cream 0.3% for plaque psoriasis to children as young as 2 | Jun 29, 2026 |
| ROIV | CLUSTER | neutral | 3/10 | Two top executives at Roivant Sciences (President & CIO and President & Immunovant CEO) sold a total of $22.15M in open- | Jun 29, 2026 |
| PHVS | CLUSTER | neutral | 3/10 | Insider cluster at Pharvaris N.V. shows two insiders selling shares totaling $584K (0.024% of market cap), with the CMO' | Jun 29, 2026 |
| ABVX | 6-K | bullish | 7/10 | Abivax reported positive topline results from Part 2 of the Phase 3 ABTECT maintenance trial for obefazimod in ulcerativ | Jun 29, 2026 |
| CYTK | CLUSTER | neutral | 2/10 | CFO Lee Sung and EVP R&D Fady Ibraham sold shares worth $3.47M combined, but this represents only 0.034% of CYTK's $10.2 | Jun 29, 2026 |
| HOWL | 144 | bearish | 6/10 | MPM Oncology Innovations Fund, a major insider, filed a Form 144 notice of intent to sell 23,248 shares of Werewolf Ther | Jun 29, 2026 |
| DYN | 144 | bearish | 4/10 | Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund I, L.P., two affiliated venture capital funds, filed Form | Jun 29, 2026 |
| OTLC | 8-K | bearish | 6/10 | Oncotelic Therapeutics entered into a securities purchase agreement with Pacific Pier Capital II, issuing a $178,410 con | Jun 29, 2026 |
| CLDI | 3 | neutral | 2/10 | Corazon (Corsee) D. Sanders filed a Form 3 initial statement of beneficial ownership with Calidi Biotherapeutics, report | Jun 29, 2026 |
| GMAB | 6-K | bullish | 7/10 | Genmab announced positive topline Phase 3 results for epcoritamab plus lenalidomide in relapsed/refractory DLBCL, meetin | Jun 29, 2026 |